Literature DB >> 21720788

Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial.

Marzieh Aghahosseini1, Ashraf Aleyassin, Sepideh Khodaverdi, Fatemeh Esfahani, Robabeh Mohammadbeigi, Shohreh Movahedi, Ali Kord Valeshabad, Atossa Mahdavi, Parvin Fallahi, Parisa Shabani, Zahra Rezaeeian, Maryam Khodaverdi.   

Abstract

PURPOSE: This study was designed to evaluate the effects of adding Estradiol (E2) supplementation to progesterone (P) on improvement of pregnancy outcomes in poor responder patients who underwent in vitro fertilization (IVF).
METHODS: In a prospective randomized clinical trial, 118 poor responder patients, older than 38 years without contraindications of estradiol consumption from Infertility clinic of a university hospital were randomly divided (by computerized software) into two groups. Control group (59 patients) received only P and intervention group (59 patients) received P and E2 (4 mg/d). Supplementation was done with 4 mg E2 in the luteal phase. Fertilization rate, implantation rate, biochemical and clinical pregnancy rates, abortion rate, ongoing pregnancy, multiple pregnancy and ectopic pregnancy rates were documented for those who completed the study protocol in each group (per protocol analysis) and compared between groups. RESULT: Fifty five patients in control group and 53 patients in intervention group successfully completed the study protocol. Treatment outcomes were not significantly different between two groups.
CONCLUSION: For poor responder women who underwent IVF, addition of E2 to P supplementation could not significantly improve pregnancy outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21720788      PMCID: PMC3169685          DOI: 10.1007/s10815-011-9595-8

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  27 in total

1.  The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.

Authors:  Lawrence Engmann; Andrea DiLuigi; David Schmidt; Claudio Benadiva; Donald Maier; John Nulsen
Journal:  Fertil Steril       Date:  2007-08-02       Impact factor: 7.329

Review 2.  How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis.

Authors:  Dimitra Kyrou; Efstratios M Kolibianakis; Christos A Venetis; Evangelos G Papanikolaou; John Bontis; Basil C Tarlatzis
Journal:  Fertil Steril       Date:  2008-07-21       Impact factor: 7.329

Review 3.  Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques.

Authors:  E S Surrey; W B Schoolcraft
Journal:  Fertil Steril       Date:  2000-04       Impact factor: 7.329

4.  The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol.

Authors:  Human M Fatemi; Michel Camus; Efstratios M Kolibianakis; Herman Tournaye; Evangelos G Papanikolaou; Patricio Donoso; Paul Devroey
Journal:  Fertil Steril       Date:  2006-11-29       Impact factor: 7.329

5.  A rapid decline in serum oestradiol concentrations around the mid-luteal phase had no adverse effect on outcome in 763 assisted reproduction cycles.

Authors:  E Hung Yu Ng; W Shu Biu Yeung; E Yee Lan Lau; W Wai Ki So; P Chung Ho
Journal:  Hum Reprod       Date:  2000-09       Impact factor: 6.918

6.  Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles.

Authors:  Ulun Ulug; Izhar Ben-Shlomo; Ersadik Turan; Halit Firat Erden; Mehmet Ali Akman; Mustafa Bahceci
Journal:  Reprod Biomed Online       Date:  2003-06       Impact factor: 3.828

7.  Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study.

Authors:  Ahmet Erdem; Mehmet Erdem; Songül Atmaca; Ismail Guler
Journal:  Fertil Steril       Date:  2008-08-09       Impact factor: 7.329

Review 8.  The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis.

Authors:  Tarek A Gelbaya; Maria Kyrgiou; Ioanna Tsoumpou; Luciano G Nardo
Journal:  Fertil Steril       Date:  2008-01-07       Impact factor: 7.329

9.  A luteal estradiol protocol for anticipated poor-responder patients may improve delivery rates.

Authors:  Micah J Hill; Grant D E McWilliams; Kathleen A Miller; Richard T Scott; John L Frattarelli
Journal:  Fertil Steril       Date:  2008-03-07       Impact factor: 7.329

Review 10.  Clinical management of low ovarian response to stimulation for IVF: a systematic review.

Authors:  B C Tarlatzis; L Zepiridis; G Grimbizis; J Bontis
Journal:  Hum Reprod Update       Date:  2003 Jan-Feb       Impact factor: 15.610

View more
  3 in total

Review 1.  Luteal phase support for assisted reproduction cycles.

Authors:  Michelle van der Linden; Karen Buckingham; Cindy Farquhar; Jan A M Kremer; Mostafa Metwally
Journal:  Cochrane Database Syst Rev       Date:  2015-07-07

2.  Plasmatic estradiol concentration in the mid-luteal phase is a good prognostic factor for clinical and ongoing pregnancies, during stimulated cycles of in vitro fertilization.

Authors:  Rodopiano S Florêncio; Melaynne S B Meira; Marcos V da Cunha; Mylena N C R Camarço; Eduardo C Castro; Marta C C F Finotti; Vinicius A de Oliveira
Journal:  JBRA Assist Reprod       Date:  2018-03-01

3.  Evaluation of growth hormone co-treatment in in vitro fertilization in patients responding better to the GnRH antagonist short protocol.

Authors:  José Fernando de Macedo; Maristela Rodrigues Oliveira; Luiz Mauro Oliveira Gomes; Gustavo Capinzaiki de Macedo; Giovanna Capinzaiki de Macedo; Daniela Oliveira Gomes; Olga Goiana Martins; Bruna Oliveira Ambrogi; Sandra Irene Sprogis Dos Santos
Journal:  JBRA Assist Reprod       Date:  2020-05-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.